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Abstract
 
Background.
 
Graft-versus-host disease (GVHD)
can be a major complication of allogeneic bone marrow
transplantation even when the donor and recipient are
siblings and share identical major histocompatibility an-
tigens. The explanation may be a mismatch of minor
histocompatibility antigens. We previously characterized
ﬁve minor histocompatibility antigens, HA-1, 2, 3, 4, and
5, that are recognized by T cells in association with the
major histocompatibility antigens HLA-A1 and A2.
 
Methods.
 
We collected peripheral-blood leukocytes
from 148 bone marrow recipients and their sibling do-
nors, who were genotypically HLA identical. Fifty pairs
were positive for HLA-A1, 117 were positive for HLA-A2,
and 19 were positive for both. The pairs were typed with
cytotoxic-T-cell clones speciﬁc for minor histocompatibil-
ity antigens HA-1, 2, 3, 4, and 5.
 
Results.
 
Mismatches of HA-3 were equally distribut-
ed among recipients in whom GVHD developed and
those in whom it did not. By contrast, a mismatch of only
HA-1 was signiﬁcantly correlated with GVHD of grade
II or higher (odds ratio, 
 
∞
 
; P
 

 
0.02) in adults. One or
more mismatches of HA-1, 2, 4, and 5 were also signiﬁ-
cantly associated with GVHD (odds ratio, 
 
∞
 
; P
 

 
0.006)
in adults. These associations were not observed in
children.
 
Conclusions.
 
A mismatch of minor histocompatibility
antigen HA-1 can cause GVHD in adult recipients of allo-
geneic bone marrow from HLA-identical donors. Pro-
spective HA-1 typing may improve donor selection and
identify recipients who are at high risk for GVHD. (N Engl
J Med 1996;334:281-5.)
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ECIPIENTS of allogeneic bone marrow grafts run
the risk of graft-versus-host disease (GVHD) or
graft failure, even when the donor and recipient have
identical major histocompatibility antigens and are
closely related.
 
1
 
 These complications may arise from dis-
parities in minor histocompatibility antigens between
donor and recipient, with the antigen present in the re-
cipient and not in the donor.
 
2,3
 
 In such cases, T cells in
the transplanted donor marrow respond to minor histo-
compatibility antigens in the recipient.
Cytotoxic T lymphocytes directed against minor his-
tocompatibility antigens of the host have been demon-
strated in blood from recipients of bone marrow from
donors who were genotypically HLA identical.
 
4-10
 
 Clones
of such cytotoxic T cells have been isolated from lym-
phocyte populations in the blood of patients with severe
GVHD. These clones have been used as reagents to
identify ﬁve non–sex-linked minor histocompatibility
antigens, designated HA-1, 2, 3, 4, and 5. Most of the cy-
totoxic-T-cell clones isolated from various patients re-
acted against HA-1.
 
11
 
 
For immune recognition, the HA-1, 2, 4, and 5 anti-
gens must be presented to cytotoxic T cells by the ma-
jor histocompatibility antigen HLA-A2. In this way they
behave like antigens recognized in an HLA-restrict-
ed fashion. The HA-1 antigen is present in 69 percent
of normal people who express HLA-A2, whereas the
frequencies of the three others in this set of HLA-A2–
restricted minor histocompatibility antigens are either
high (95 percent for HA-2) or low (16 percent for HA-
4 and 7 percent for HA-5). The HLA-A1–restricted mi-
nor histocompatibility antigen HA-3 occurs in 88 per-
cent of persons positive for HLA-A1.
 
11
 
 HA-1, 2, 4, and
5 are inherited independently of the HLA genes; each
of them is a single gene, and none have a locus within
the HLA region.
 
12
 
 
We investigated whether mismatching of minor his-
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tocompatibility antigens contributes to acute GVHD
(grade II or higher) in recipients of genotypically HLA-
identical bone marrow. We collected peripheral-blood
lymphocytes from 148 donor–recipient pairs of siblings
who were positive for HLA-A1 or A2 and who were gen-
otypically HLA identical. The lymphocytes from these
donor–recipient pairs were analyzed by means of a series
of cytotoxic-T-cell clones speciﬁc for ﬁve well-deﬁned mi-
nor histocompatibility antigens, HA-1, 2, 3, 4, and 5. 
 
M
 
ETHODS
 
Patients
 
We studied 148 recipients of bone marrow and their sibling donors,
who were genotypically HLA identical, at Leiden University Hospital,
Leiden, the Netherlands; Kantonsspital, Basel, Switzerland; and
Johns Hopkins Oncology Center, Baltimore. The donor–recipient
pairs were selected on the basis of the presence of HLA-A1 or A2 (or
both), which are the HLA restriction molecules for minor histocom-
patibility antigens HA-3 (HLA-A1) and HA-1, 2, 4, and 5 (HLA-A2).
 
11
 
Fifty pairs were positive for HLA-A1, 117 pairs were positive for
HLA-A2, and 19 pairs were positive for both (Table 1). No other ex-
clusion criteria were applied. There were 105 pairs of adults and 43
pairs of children (age, 
 

 
16 years). The recipients underwent bone
marrow transplantation between 1982 and 1990 for acute lymphocytic
leukemia, acute myelocytic leukemia, chronic myelocytic leukemia,
non-Hodgkin’s lymphoma, or aplastic anemia. Consecutive patients
were selected for the study. None of the recipients received bone mar-
row depleted of T cells. As prophylaxis against GVHD, they received
methotrexate (51 patients), cyclosporine (80 patients), or both (17 pa-
tients); 6 patients also received prednisolone. In the assessment of
GVHD, a grade of 0 or I was considered to indicate the absence
of such disease, and a grade of II or higher its presence. All cases of
chronic GVHD occurred in patients with grade II or higher acute
GVHD. The relatively high frequency of GVHD in our study (60.7
percent) is most likely due to the use of methotrexate or cyclosporine
as the principal form of prophylaxis.
 
13
 
 
 
Blood Samples
 
Blood samples were obtained from the patients and their sibling do-
nors before bone marrow transplantation and treated with heparin.
The search for and selection of an HLA-identical sibling donor were
based on HLA typing for the HLA-A, B, and DR antigens of the pa-
tients’ families. Peripheral-blood leukocytes were isolated by Ficoll–
Isopaque density-gradient centrifugation, washed, and resuspended in
RPMI-1640 medium with 10 percent dimethyl sulfoxide for cryopres-
ervation in liquid nitrogen.
 
Cytotoxic-T-Cell Clones Speciﬁc for HA-1, 2, 3, 4, and 5
 
The cytotoxic-T-cell clones speciﬁc for HA-1, 2, 3, 4, and 5 have
been described in detail elsewhere.
 
11,14
 
 These clones were assayed for
their ability to lyse phytohemagglutinin-stimulated peripheral-blood
leukocytes from donors and recipients at various effector-to-target ra-
tios. The leukocytes were labeled with chromium-51, and the extent
of lysis was measured with a standard chromium-release assay.
 
15
 
 The
assays were carried out retrospectively without knowledge of the clin-
ical results. All experiments were repeated at least twice. A minor his-
tocompatibility antigen was considered to be present when the per-
centage of lysis was at least 25 percent at the lowest effector-to-target
ratio (i.e., 1 to 1).
 
Statistical Analysis
 
For this analysis of mismatching of minor histocompatibility anti-
gens and GVHD, we considered a grade of II or higher as indicating
the presence of GVHD.
 
16,17
 
 Each donor–recipient pair was categorized
as matched or mismatched for each of the minor histocompatibility
antigens. When the recipient was positive for the antigen and the do-
nor was negative, the pair was counted as mismatched. Otherwise the
pair was considered to be matched. We obtained maximum-likelihood
estimates of the odds ratios for the association between match–mis-
match status and GVHD, with stratiﬁcation according to the age
(adult or child) of the recipient. These ratios are presented with exact
95 percent conﬁdence intervals and exact two-sided P values, calcu-
lated with the Egret statistical package.
 
18
 
 Heterogeneity between stra-
ta was evaluated with Zelen’s exact test.
 
19
 
 Patients with missing values
were excluded from the analysis of any of the minor histocompatibil-
ity antigens for which data were missing.
 
R
 
ESULTS
 
We typed 148 pairs of bone marrow donors and re-
cipients who were genotypically HLA identical for
HLA-A1 and A2 (Table 1). The HLA-A1–positive do-
nor pairs were typed for HA-3, and the HLA-A2–posi-
tive pairs were typed for HA-1, 2, 4, and 5 (Table 2).
Male recipients were considered to have H-Y, a sex-
linked minor histocompatibility antigen, and were called
H-Y–positive; female patients were considered to be
H-Y–negative. The results were then evaluated to deter-
mine whether they were correlated with the develop-
ment of GVHD after bone marrow transplantation.
We found no correlation of HA-3–antigen status with
GVHD (Table 3). The HA-3–speciﬁc cytotoxic T cells
we used to identify HA-3–positive donors and recipi-
ents were originally generated in a patient with severe
acute GVHD. Nevertheless, the typing analysis in
HLA-A1–positive pairs revealed an HA-3 mismatch in
three patients with GVHD and four patients with no
clinical signs of the disease (Table 3). We also noted
this lack of correlation in our earlier studies.
 
14
 
 
We found no inﬂuence of sex discordance in male
(H-Y–positive) recipients of bone marrow from female
(H-Y–negative) donors on the occurrence of GVHD.
The H-Y antigen is inﬂuential in transplantation and
can lead to graft rejection and GVHD.
 
14
 
 Among the
HLA-A1–positive pairs mismatched for sex (male re-
cipient, female donor), the number of recipients with
GVHD was similar to the number without GVHD (six
vs. ﬁve) (Table 3); similar patterns of distribution were
 
Table 1. Status of Major Histocompatibility
Antigens in 148 Donor–Recipient Pairs.
 
HLA-A1
S
 
TATUS
 
HLA-A2 S
 
TATUS
 
 
 
TOTAL
 
no. of pairs
 

 
19 31 50
 

 
98 0 98
Total 117 31 148
 
*The HA-3 antigen is recognized in HLA-A1–positive persons, and the
HA-1, 2, 4, and 5 antigens are recognized in HLA-A2–positive persons.
 
Table 2. Status of Minor Histocompatibility Anti-
gens in 50 HLA-A1–Positive and 117 HLA-A2–
Positive Donor–Recipient Pairs.
 
*
 
HLA T
 
YPE
 
N
 
O
 
. 
 
OF
 
P
 
AIRS
 
HA-1 HA-2 HA-3 HA-4 HA-5
 
HLA-A1 50
 
    
 
HLA-A2 117
 
    
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found in HLA-A2–positive male recipients of bone mar-
row from female donors (Table 4).
The effect of mismatches of HA-1, 2, 4, and 5 was
studied in HLA-A2–positive pairs (Table 4). Since the
numbers of mismatches for HA-2, 4, and 5 were small,
we focused ﬁrst on the effect of HA-1 mismatches. There
was a signiﬁcant association between an HA-1 mis-
match and GVHD in adults (odds ratio, 
 
∞
 
; 95 percent
conﬁdence interval, 1.3 to 
 
∞
 
; P
 

 
0.02) but not in chil-
dren (odds ratio, 1.2; 95 percent conﬁdence interval,
0.02 to 26; P
 

 
1.00) (Table 5). Zelen’s exact test (which
measures heterogeneity between groups) showed no sig-
niﬁcant difference between the odds ratios in adults and
children. The pooled odds ratio obtained from a strati-
ﬁed analysis was 5.4 (95 percent conﬁdence interval, 1.0
to 56; P
 

 
0.05). It was notable that GVHD developed in
all 10 cases in which the adult bone marrow recipient
was HA-1–positive and the adult bone marrow donor
was HA-1–negative (Table 5).
We also analyzed the effect of a mismatch of one or
more of the minor histocompatibility antigens HA-1, 2,
4, and 5. We considered a mismatch to be present if the
donor–recipient pairs were mismatched for at least one
of these antigens. We considered a match to be present
if the pairs were matched for all four antigens. Of the
115 HLA-A2–positive pairs tested for HA-1, 17 could
not be classiﬁed because of missing information. The re-
sults for the remaining 98 pairs are shown in Table 6.
For the group as a whole there was a signiﬁcant associ-
ation between a mismatch and GVHD (odds ratio, 6.4;
95 percent conﬁdence interval, 1.4 to
43; P
 

 
0.01). The odds ratio in chil-
dren was 1.9 (95 percent conﬁdence
interval, 0.1 to 22; P
 

 
0.07), and in
adults it was inﬁnite (95 percent con-
ﬁdence interval, 1.8 to 
 
∞
 
; P
 

 
0.006).
Again, Zelen’s test did not show a
signiﬁcant difference between the
odds ratios in children and adults.
The ﬁnding of a mismatch of more
than one of the four antigens (HA-1,
2, 4, and 5) was slightly more predic-
tive of GVHD than was the ﬁnding
of an HA-1 mismatch alone (Table
5). GVHD developed in all 12 adult bone marrow re-
cipients who were positive for at least one of the four
antigens and whose donors were negative for those an-
tigens.
 
D
 
ISCUSSION
 
Our study demonstrates a signiﬁcant correlation be-
tween mismatches of minor histocompatibility antigens
HA-1, 2, 4, and 5 in HLA-A2–positive donor–recipient
pairs and GVHD. The frequency of the HLA-A2 phe-
notype is 49 percent in the white population. Among
the 12 adult recipients with a mismatch of these anti-
gens and GVHD, 8 had only an HA-1 mismatch; 1 had
mismatches of HA-1 and 4, and 1 mismatches of HA-1
and 5; the 2 remaining recipients were matched for
HA-1 but mismatched for HA-2 or 5.
The impact of mismatches of minor histocompati-
bility antigens on the development of GVHD is best
studied in pairs of siblings who are genotypically HLA
identical. In such pairs the effect of the disparity
would not be overshadowed by unknown mismatches
of major histocompatibility antigens. Siblings discord-
ant for minor histocompatibility antigens are possible
only in families in which both parents are heterozy-
gotes or one parent is heterozygous and the other ho-
mozygous for the minor-histocompatibility-antigen al-
lele.
 
12
 
 A minor histocompatibility antigen is of clinical
interest only if it is immunogenic and when it has a
moderately frequent distribution in the population. El-
kins et al.
 
20
 
 failed to demonstrate any inﬂuence of mis-
matching of the minor histocompatibility antigen W1
on GVHD because the number of W1 mismatches was
too low (i.e., there was a high phenotypic frequency).
By contrast the HA-1 antigen fulﬁlls two of the condi-
tions required for the induction of GVHD: it is immu-
nogenic and has a moderate phenotypic frequency (69
percent).
Other elements of the immunogenic potency of the
HA-1 antigen must also be considered. For example, a
response by cytotoxic-T-cell precursors that are speciﬁc
for a minor histocompatibility antigen requires helper
T cells. A large number of helper T cells, due to cross-
reactivity or hyperactivation, might increase the fre-
quency of cytotoxic-T-cell precursors speciﬁc for HA-1.
Cross-reactivity of cytotoxic T cells themselves seems
unlikely since, at least in vitro, the recognition of HA-1
 
*A plus sign indicates the presence of an antigen, and a minus sign its absence.
 
Table 4. Results of HA-1, 2, 4, and 5 Typing and GVHD Status in 117 HLA-A2–Pos-
itive Donor–Recipient Pairs.
 
R
 
ESULTS
 
 
 
OF
 
 T
 
YPING
 
 
(D
 
ONOR
 
/R
 
ECIPIENT
 
)* HA-1 HA-2 HA-4 HA-5 H-Y
GVHD
 
NO
 
GVHD GVHD
 
NO
 
GVHD GVHD
 
NO
 
GVHD GVHD
 
NO
 
GVHD GVHD
 
NO
 
GVHD
 

 
27 19 55 49 4 7 7 5 16 11
 

 
19 26 5 2 47 35 43 37 17 12
 

 
/
 

 
6 5 2 1 0 0 0 0 18 12
 

 
/
 

 
11 2 2 1 1 0 2 0 18 10
Not tested 1 1 0 0 12 11 12 11 2 1
 
*A plus sign indicates the presence of the antigen, and a minus
sign its absence.
 
Table 3. Results of HA-3 Typing According
to GVHD Status in 50 HLA-A1–Positive Do-
nor–Recipient Pairs.
 
R
 
ESULTS
 
 
 
OF
 
 T
 
YPING
 
 
(D
 
ONOR
 
/R
 
ECIPIENT
 
)* HA-3 H-Y
GVHD
 
NO
 
GVHD GVHD
 
NO
 
GVHD
 
no. of pairs
 

 
/
 

 
20 15 5 9
 

 
2 0 9 7
 

 
/
 

 
3 1 8 1
 

 
/
 

 
3 4 6 5
Not tested 0 2 0 0
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is governed solely by HLA-A2.1, and HA-1 segregates
in families in a mendelian fashion.
 
11,12
 
The distribution of HA-1 in tissue might explain its
correlation with GVHD. HA-1 and HA-2 are expressed
only on cells derived from hematopoietic precursors, in-
cluding dendritic cells and epidermal Langerhans’
cells.
 
21,22
 
 Since the chief function of the latter cells is to
present antigens to T cells, they are plausible candi-
dates for eliciting a graft-versus-host reaction from do-
nor T cells. The H-Y and HA-3 antigens occur on hem-
atopoietic and nonhematopoietic cells. In parenchymal
tissues of the host, they might induce immune tolerance
in antihost cytotoxic T cells.
 
23
 
 Such a mechanism can
account for the absence of correlation between HA-3
and H-Y mismatches and GVHD. However, our results
for H-Y are not in line with the report of an increased
frequency of GVHD in male recipients of marrow from
female donors.
 
24
 
 This effect was seen primarily with
female donors who had been pregnant or received a
transfusion,
 
24
 
 but it was not observed in all studies.
 
25
 
 
It has been suggested that GVHD is less frequent in
young patients than in adult recipients of allogeneic
bone marrow.
 
24,25
 
 Almost all of the children in our
study were seen at the Department of Pediatrics at
Leiden University Hospital, where the occurrence of
GVHD is reduced because complete rather than se-
lective decontamination of the intestinal tract is per-
formed.
 
26
 
 Our data are ambiguous with respect to the
effect of mismatches of minor histocompatibility anti-
gens on GVHD in children. The odds ratio of GVHD
with a mismatch of HA-1, 2, 4, or 5 in this group was
not signiﬁcantly different from 1 (odds ratio, 1.9; 95 per-
cent conﬁdence interval, 0.1 to 22), but there was no
signiﬁcant difference between the odds ratio in children
and the odds ratio in adults (P
 

 
0.21 by Zelen’s test).
This ambiguity is due to the small number (n
 

 
34) of
children in the study.
In conclusion, our data demonstrate an association
between the presence of an HA-1 mismatch and the oc-
currence of GVHD in adult recipients of bone marrow
from genotypically HLA-identical donors. In all cases
in which an HA-1–positive patient received bone mar-
row from an HA-1–negative donor, GVHD (grade II or
higher) developed. Of 71 adult donor–recipient pairs
matched for HA-1, 28 of the recipients showed no clin-
ical signs of GVHD. Our results suggest the clinical
usefulness of HA-1 typing for HLA-A2–positive do-
nor–recipient pairs to identify HLA-A2–positive recip-
ients who are at high risk for GVHD. The HA-1 cyto-
toxic-T-cell clones that we used are available to others
for typing. Molecular typing of these minor histocom-
patibility antigens may soon be feasible.
 
27,28
 
 The HA-2
antigen has already been identiﬁed and appears to orig-
inate from a member of the class I myosin family, a
large family of proteins involved in cell locomotion and
organelle transport.
 
27
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